are currently pregnant or breastfeeding or plan to become pregnant within 30 days after the second dose of the trial vaccine. currently receiving or receiving other vaccines, including streptococcus pneumoniae vaccine. have used any blood products or intravenous immunoglobulin within 12 weeks before entering the test. receive concurrent immunosuppressive or immunomodulatory therapy (including steroid prednisone, targeted drugs such as infliximab, adalimumab, etanercept) within 12 weeks. immunosuppressive diseases or immune insufficiency states, including hematological malignancies, parenchymal organs, bone marrow transplant history or asplenia, autoimmune diseases (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis, autoimmune thyroiditis, etc.) and human immunodeficiency virus infection. bleeding disease and assessed as a contraindication to prohibit the use of intramuscular injection or blood draw. other condition, such as physical examination or instability according to the trial investigator's judgment, or participation in this trial may adversely affect the safety of subjects, fail to comply with trial regulations, or interfere with trial evaluation indicators. the subject is known to have been infected with severe acute respiratory syndrome coronavirus type 2 (sars-cov-2).

are currently pregnant or breastfeeding or plan to become pregnant within 30 days after the second dose of the trial vaccine. currently receiving or receiving other vaccines, including streptococcus pneumoniae vaccine. have used any blood products or intravenous immunoglobulin within 12 weeks before entering the test. receive concurrent immunosuppressive or immunomodulatory therapy (including steroid prednisone, targeted drugs such as infliximab, adalimumab, etanercept) within 12 weeks. immunosuppressive diseases or immune insufficiency states, including hematological malignancies, parenchymal organs, bone marrow transplant history or asplenia, autoimmune diseases (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis, autoimmune thyroiditis, etc.) and human immunodeficiency virus infection. bleeding disease and assessed as a contraindication to prohibit the use of intramuscular injection or blood draw. other condition, such as physical examination or instability according to the trial investigator's judgment, or participation in this trial may adversely affect the safety of subjects, fail to comply with trial regulations, or interfere with trial evaluation indicators. the subject is known to have been infected with severe acute respiratory syndrome coronavirus type 2 (sars-cov-2).

1. are currently pregnant or breastfeeding or plan to become pregnant within 30 days after the second dose of the trial vaccine. 2. currently receiving or receiving other vaccines, including streptococcus pneumoniae vaccine. 3. have used any blood products or intravenous immunoglobulin within 12 weeks before entering the test. receive concurrent immunosuppressive or immunomodulatory therapy (including steroid prednisone, targeted drugs such as infliximab, adalimumab, etanercept) within 12 weeks. 4. immunosuppressive diseases or immune insufficiency states, including hematological malignancies, parenchymal organs, bone marrow transplant history or asplenia, autoimmune diseases (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis, autoimmune thyroiditis, etc.) and human immunodeficiency virus infection. 5. bleeding disease and assessed as a contraindication to prohibit the use of intramuscular injection or blood draw. 6. other condition, such as physical examination or instability according to the trial investigator's judgment, or participation in this trial may adversely affect the safety of subjects, fail to comply with trial regulations, or interfere with trial evaluation indicators. 7. the subject is known to have been infected with severe acute respiratory syndrome coronavirus type 2 (sars-cov-2).

1. are currently pregnant or breastfeeding or plan to become pregnant within 30 days after the second dose of the trial vaccine. 2. currently receiving or receiving other vaccines, including streptococcus pneumoniae vaccine. 3. have used any blood products or intravenous immunoglobulin within 12 weeks before entering the test. receive concurrent immunosuppressive or immunomodulatory therapy (including steroid prednisone, targeted drugs such as infliximab, adalimumab, etanercept) within 12 weeks. 4. immunosuppressive diseases or immune insufficiency states, including hematological malignancies, parenchymal organs, bone marrow transplant history or asplenia, autoimmune diseases (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis, autoimmune thyroiditis, etc.) and human immunodeficiency virus infection. 5. bleeding disease and assessed as a contraindication to prohibit the use of intramuscular injection or blood draw. 6. other condition, such as physical examination or instability according to the trial investigator's judgment, or participation in this trial may adversely affect the safety of subjects, fail to comply with trial regulations, or interfere with trial evaluation indicators. 7. the subject is known to have been infected with severe acute respiratory syndrome coronavirus type 2 (sars-cov-2).